Clinical Study
Testing a Study Drug, BMS-986278 for People with Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis is a disease that causes the lungs to scar and harden. This study will test a drug called BMS-986278 to treat people with this disease. The study wants to see if the drug will help people with the disease and is safe. Being in the study lasts at least 14 months and up to about 4 years. There will be at least 13 in-person visits at the study clinic in the first 52 weeks then every 12 weeks up to about 4 years. Medical tests will be done to track the health of participants.
For more information contact:
Cassie Larsen
cassie.larsen@hsc.utah.edu
18015815811
IRB#: IRB_00171168
| PI: Mary Beth Scholand
| Department: PULMONARY
| Approval Date: 2024-03-06 07:00:00
Specialties: Pulmonary
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 40 years and older
- Diagnosis of Idiopathic Pulmonary Fibrosis within the past 7 years before participation
- If on pirfenidone or nintedanib medication, is on a stable dose for at least 90 days before participation
- If not on pirfenidone or nintedanib medication, cannot have received either medication within 28 days before participation
- Must agree to a use specific birth control
Exclusion Criteria:
- Have Pulmonary arterial hypertension (high blood pressure that affects the lungs and heart)
- Pregnant or breastfeeding
- History of stroke 3 months before participation
- Serious heart disease 6 months before participation
- Prior use of the study drug BMS-986278
Will I be paid for my time?
Yes